RE
TXG icon

RBC Europe’s 10x Genomics TXG Stock Holding History

RBC Europe’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-110
Closed -$16K – 1122
2021
Q3 		$16K Buy
110
+65
+144% +$11.2K ﹤0.01% 844
2021
Q2 		$8.81K Hold
45
– – ﹤0.01% 979
2021
Q1 		$8.14K Hold
45
– – ﹤0.01% 945
2020
Q4 		$6.37K Buy
+45
New +$6.53K ﹤0.01% 939

Other funds holding TXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

RBC Europe's TXG Position: Q4 2021 in Review

RBC Europe sold out of 10x Genomics (TXG) in Q4 2021, closing a stake of 110 shares — an estimated $16K sold.

RBC Europe first reported a position in TXG in Q4 2020 and held it in 4 quarters. The position peaked at $16K in Q3 2021. 365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

  • RBC Europe reported no remaining 10x Genomics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 110 10x Genomics shares in Q4 2021, an estimated $16K.
  • RBC Europe first reported a position in 10x Genomics in Q4 2020 and held it in 4 quarters.
  • RBC Europe's 10x Genomics position peaked at $16K in Q3 2021.
  • 365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.